Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A known ✓ | Q03164 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL4968361 | 1.00 | POLB (0.40) | POLBGAAMAPTNAPEPLDNPC1 | |
| Fumaric Acid SCHEMBL2908209 | 1.00 | POLB (0.40) | POLBGAAMAPTNAPEPLDNPC1 | |
| SCHEMBL2707104 | 0.90 | SIGMAR1 (0.40) | POLBGAAMAPTNPC1SMN1; SMN2 | |
| SCHEMBL6553147 | 0.90 | SIGMAR1 (0.40) | POLBGAAMAPTNPC1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9424101 | 0.89 | SIGMAR1 (0.39) | POLBGAAMAPTNPC1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9424098 | 0.89 | SIGMAR1 (0.39) | POLBGAAMAPTNPC1SMN1; SMN2 | |
| Fumaric Acid SCHEMBL17078223 | 0.84 | POLB (0.39) | POLBGAAMAPTNPC1SMN1; SMN2 | |
| Fumaric Acid SCHEMBL6139704 | 0.81 | LMNA (0.43) | POLBGAAMAPTNAPEPLDNPC1 | |
| Fumaric Acid SCHEMBL6139699 | 0.81 | LMNA (0.43) | POLBGAAMAPTNAPEPLDNPC1 | |
| SCHEMBL8423965 | 0.80 | ALDH1A1 (0.40) | POLBGAAMAPTNAPEPLDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4483376-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | García Sada, Fernando (MX) | 2025-01-01 | — | — | EP | claimed |
| CN-118922890-A | Measurement, diagnosis, treatment and management of metabolic syndrome | 费尔南多·加西亚·萨达 | 2024-11-08 | — | — | CN | claimed |
| WO-2023161832-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | GARCIA SADA FERNANDO (MX) | 2023-08-31 | — | — | WO | claimed |
| US-20230266340-A1 | Measurement, Diagnosis, Treatment and Management of Metabolic Syndrome | SILTI AG (CH) | 2023-08-24 | — | — | US | claimed |
| US-20040077730-A1 | Carbocyclic halo amines such as N,N-dimethyl-1-(1-(4-chloro-phenyl)cyclobutyl)-3-methylbutyl amine hydrochloride, used for reducing insulin resistance in humans having diabetes | BAILEY CLIFFORD JAMES (GB) | 2004-04-22 | — | — | US | claimed |
| EP-0946181-B1 | USE OF 2-(2-MORPHOLINOPHENYL) GUANIDINE DERIVATIVES FOR THE TREATMENT OF DIABETES COMPLICATIONS | KNOLL GMBH (DE) | 2004-02-25 | — | — | EP | claimed |
| US-6617360-B1 | Arylcyclobutylalkylamines, especially sibutramine; and a an oral insulin secretagogue such as 1,1-dimethyl-2-(2-morpholinophenyl)guanidine fumarate or a sulfonyl urea, or an insulin sensitizer | KNOLL AKTIENGESELLSCHAFT (DE) | 2003-09-09 | — | — | US | claimed |
| US-6133267-A | Use of 2-(2-morpholinophenyl) guanidine derivatives for the treatment of diabetes complications | KNOLL AKTIENGESELLSCHAFT (DE) | 2000-10-17 | — | — | US | claimed |
| EP-4483376-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | García Sada, Fernando (MX) | 2025-01-01 | — | — | EP | disclosed |
| CN-118922890-A | Measurement, diagnosis, treatment and management of metabolic syndrome | 费尔南多·加西亚·萨达 | 2024-11-08 | — | — | CN | disclosed |
| WO-2023161832-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | GARCIA SADA FERNANDO (MX) | 2023-08-31 | — | — | WO | disclosed |
| US-20230265153-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD (GB) | 2023-08-24 | — | — | US | disclosed |
| US-20230266340-A1 | Measurement, Diagnosis, Treatment and Management of Metabolic Syndrome | SILTI AG (CH) | 2023-08-24 | — | — | US | disclosed |
| US-11548928-B2 | Engineered platelets for targeted delivery of a therapeutic agent | JPV01 LTD. (GB) | 2023-01-10 | — | — | US | disclosed |
| US-6174925-B1 | REDUCING INSULIN RESISTANCE IN HUMANS IN WHOM IMPAIRED GLUCOSE TOLERANCE OR NON-INSULIN DEPENDENT DIABETES MELLITUS HAVE NOT PRESENTED BUT IN WHOM THERE IS INCREASED RISK OF DEVELOPING SUCH CONDITIONS BY ADMINISTERING SIBUTRAMINE ANALOGUE | KNOLL AKTIENGESELLSCHAFT (DE) | 2001-01-16 | — | — | US | disclosed |
| US-6133267-A | Use of 2-(2-morpholinophenyl) guanidine derivatives for the treatment of diabetes complications | KNOLL AKTIENGESELLSCHAFT (DE) | 2000-10-17 | — | — | US | disclosed |
| EP-0946181-A1 | USE OF 2-(2-MORPHOLINOPHENYL) GUANIDINE DERIVATIVES FOR THE TREATMENT OF DIABETES COMPLICATIONS | KNOLL AKTIENGESELLSCHAFT (DE) | 1999-10-06 | — | — | EP | disclosed |
| EP-0927028-A1 | USE OF SIBUTRAMINE ANALOGUES TO PREVENT THE DEVELOPMENT OF DIABETES | KNOLL AKTIENGESELLSCHAFT (DE) | 1999-07-07 | — | — | EP | disclosed |
| WO-1998026782-A1 | USE OF 2-(2-MORPHOLINOPHENYL) GUANIDINE DERIVATIVES FOR THE TREATMENT OF DIABETES COMPLICATIONS | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-06-25 | — | — | WO | disclosed |
| WO-1998011884-A1 | USE OF SIBUTRAMINE ANALOGUES TO PREVENT THE DEVELOPMENT OF DIABETES | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077730-A1 | Carbocyclic halo amines such as N,N-dimethyl-1-(1-(4-chloro-phenyl)cyclobutyl)-3-methylbutyl amine hydrochloride, used for reducing insulin resistance in humans having diabetes | GPR119, CLIC1, SLC5A1 | MEN1 274/4885KMT2A 1204/4885POLB 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.